Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,015 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: AMD Clear all
Completed Phase 1 Interventional Results available

Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema

NCT00826618
View directory record Official record
Conditions
Uveitic Cystoid Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Miami, Florida • Palm Beach Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 4 Interventional Results available

Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO

NCT02503540
View directory record Official record
Conditions
Retinal Vein Occlusion, Diabetic Macular Edema, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
Interventions
Aflibercept
Drug
Lead sponsor
Justis Ehlers
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Sep 2, 2026, 1:37 AM EDT
Not listed Phase 4 Interventional

Post Intravitreal Injection Topical NSAID vs. Patching

NCT03918590
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX), Theratears tear drop, (Akron, Ann 111 Arbor, MI), patching
Drug · Other
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)

NCT01552408
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Sep 2, 2026, 1:37 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals

NCT05763940
View directory record Official record
Conditions
Dry Eye Syndromes, Age-Related Macular Degeneration, Omega 3 Index
Interventions
OmegaBoost, Nature Made (soft gel), Nature Made (gummy)
Dietary Supplement
Lead sponsor
Western University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration

NCT01773954
View directory record Official record
Conditions
Age-Related Macular Degeneration, Macular Degeneration
Interventions
Intravitreal Aflibercept Injection
Drug
Lead sponsor
MidAtlantic Retina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Cherry Hill, New Jersey • Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 2, 2026, 1:37 AM EDT
Completed No phase listed Observational Results available

Patients With Geographic Atrophy and Their Patient Journey in the United States (US)

NCT05891275
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
68,563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 2, 2026, 1:37 AM EDT
Completed No phase listed Observational

Non-exudative Age-related Macular Degeneration

NCT01712841
View directory record Official record
Conditions
Non-exudative Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
60 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 2 Interventional Results available

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion

NCT04085341
View directory record Official record
Conditions
Diabetic Macular Edema, Retina Vein Occlusion
Interventions
GB-102
Drug
Lead sponsor
Graybug Vision
Industry
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Phoenix, Arizona • Savannah, Georgia • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 2 Interventional Results available

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

NCT01527500
View directory record Official record
Conditions
Geographic Atrophy, Age-related Macular Degeneration
Interventions
LFG316, Sham, LFG316 Lower dose
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD

NCT00320775
View directory record Official record
Conditions
Macular Degeneration
Interventions
VEGF Trap
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Tuscon, Arizona • Loma Linda, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 2, 2026, 1:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)

NCT03322930
View directory record Official record
Conditions
Retinitis Pigmentosa, AMD
Interventions
Rod sensitivity
Diagnostic Test
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
10 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Sep 2, 2026, 1:37 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma

NCT06593405
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
occupational therapy interventions for low vision care
Combination Product
Lead sponsor
MCPHS University
Other
Eligibility
50 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 2, 2026, 1:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration

NCT01115231
View directory record Official record
Conditions
Macular Degeneration
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 80 Years
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
2
States / cities
Charleston, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration

NCT02569892
View directory record Official record
Conditions
Macular Degeneration, Retinal Drusen
Interventions
Pascal Retinal Laser Photocoagulator
Device
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 2, 2026, 1:37 AM EDT
Terminated Phase 2 Interventional

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

NCT01624636
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Placebo, LFG316
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Phoenix, Arizona • Winter Haven, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 3 Interventional Results available

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

NCT00509795
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
1,217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
176
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Sep 2, 2026, 1:37 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy

NCT00329511
View directory record Official record
Conditions
Hypertension
Interventions
methyldopa vs. clonidine, clonidine patch
Drug
Lead sponsor
Afshan B. Hameed, M.D.
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Sep 2, 2026, 1:37 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04603937
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
40
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 2, 2026, 1:37 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention

NCT03859245
View directory record Official record
Conditions
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
Interventions
Photobiomodulation, Ketogenic diet
Behavioral
Lead sponsor
Bristlecone Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Eagan, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Sep 2, 2026, 1:37 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

NCT07158775
View directory record Official record
Conditions
Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Interventions
BS01, Sham procedure control
Biological · Other
Lead sponsor
Bionic Sight LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 2 Interventional

Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

NCT05891548
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
CLS-AX, Aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Bakersfield, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT01342926
View directory record Official record
Conditions
Atrophy, Geographic
Interventions
GSK933776, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
55 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Arcadia, California • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Sep 2, 2026, 1:37 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility Study of a Remote Behavioral Dietary Intervention in Patients With Early to Intermediate AMD: Glucose Lowering for Vision Extension

NCT07605468
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Low glycemic Mediterranean diet behavioral modification
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
55 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 2, 2026, 1:37 AM EDT